Sort
10,766 grants matching “checkpoint inhibitor”
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$946,097Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2020 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability
$944,561Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · R35 · FY2020 · CA
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.
$943,101Alexander H. Stegh · Washington University · R01 · FY2025 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
$942,132Pablo Tamayo · University Of California, San Diego · U01 · FY2021 · CA
Mechanisms of chromosome segregation, aneuploidy, and tumorigenesis
$941,397Don W. Cleveland · University Of California, San Diego · R35 · FY2022 · GM
Promoting Kidney Transplantation Tolerance Through Novel Immunomodulation and Cellular Therapy
$939,602Andrew B Adams · University Of Minnesota · U19 · FY2024 · AI
Deciphering the crosstalk between bacteria and their mammalian hosts
$939,000Aaron Thomas Whiteley · University Of Colorado · DP2 · FY2025 · AT
Wee1 and HDAC inhibition in relapsed/refractory AML
$938,670Steven Grant · Virginia Commonwealth University · UH2 · FY2015 · TR
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
$938,597Christopher D Pack · Metaclipse Therapeutics Corporation · R44 · FY2022 · CA
Molecular Pathogenesis of Neoplasia
$937,516Richard Youle · National Institute Of Neurological Disorders And Stroke · ZIA · FY2019 · NS
Next Generation Cancer Immunotherapies to Defeat Melanoma
$936,000Antoni Ribas · University Of California Los Angeles · R35 · FY2025 · CA
Next Generation Cancer Immunotherapies to Defeat Melanoma
$936,000Antoni Ribas · University Of California Los Angeles · R35 · FY2022 · CA
Promoting Kidney Transplantation Tolerance Through Novel Immunomodulation and Cellular Therapy
$935,944Andrew B Adams · University Of Minnesota · U19 · FY2023 · AI
Radiation-induced translational control of gene expression
$935,346Philip Tofilon · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Metabolic reprogramming of the tumor microenvironment and therapy resistance
$934,799Ernst Lengyel · University Of Chicago · R35 · FY2024 · CA
Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
$933,896Darell D Bigner · Duke University · R35 · FY2016 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
$932,751Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · R44 · FY2024 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
$932,751Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · R44 · FY2023 · CA
Systems genetics analysis of tumor evolution in the mouse
$931,980Allan Balmain · University Of California, San Francisco · R35 · FY2022 · CA
Systems genetics analysis of tumor evolution in the mouse
$931,980Allan Balmain · University Of California, San Francisco · R35 · FY2023 · CA
Strategies for improving early detection, diagnosis and treatment of liver cancer
$930,599Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Understanding and Exploiting Loss of Y in Cancer
$930,500Dan Theodorescu · University Of Arizona · R35 · FY2025 · CA
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$929,563William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2016 · CA
Initiation of DNA replication in Mammalian Cells
$926,998Mirit Aladjem · Basic Sciences · Z01 · FY2007 · CA
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
$925,398Thomas M Roberts · Dana-Farber Cancer Inst · R35 · FY2019 · CA